Nurtec ODT Missed-Dose Protocol: What to Do When You Miss a Rimegepant Dose

What Rimegepant Actually Is and Why It Matters for Women

Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. It is the first drug approved by the FDA for both acute migraine treatment and migraine prevention in the same molecule and the same dose. Most women who use it for prevention take one 75 mg orally dissolving tablet every other day.

Migraine is not gender-neutral. Women are three times more likely than men to experience migraine, and roughly 50 to 60 percent of women with migraine report attacks that cluster around menstruation, driven by the estrogen withdrawal that occurs in the late luteal phase. CGRP levels rise during a migraine attack, and estrogen modulates CGRP expression and release in trigeminal neurons, which is one reason hormonal fluctuations are such a reliable migraine trigger in women. Rimegepant targets that pathway directly.

How Rimegepant Differs From Triptans

Triptans are serotonin receptor agonists that cause vasoconstriction. That mechanism is the reason triptans carry a cardiovascular contraindication, and it is also why they are used cautiously in women who have migraine with aura, who already carry an elevated stroke risk compared with migraine-without-aura patients. Rimegepant does not constrict blood vessels. It blocks CGRP from binding its receptor, interrupting the peripheral and central pain signaling cascade without vascular effects. That distinction is clinically meaningful for women who are excluded from triptans because of cardiovascular risk factors, uncontrolled hypertension, or a personal history of migraine with aura and concomitant oral contraceptive use.

The Orally Dissolving Tablet Format

The ODT formulation dissolves on the tongue without water. This matters during a migraine attack when nausea makes swallowing tablets difficult. The tablet should be placed on or under the tongue and allowed to dissolve. Do not push it through the blister foil. Press the foil back to expose the tablet, then handle it gently, because moisture from fingers can begin dissolving it before it reaches your mouth.

How Nurtec ODT Works: The CGRP Mechanism in Women

CGRP is a 37-amino-acid neuropeptide released from trigeminal nerve endings during a migraine attack. It dilates intracranial blood vessels, activates mast cells in the dura, and drives neurogenic inflammation that makes pain signals self-sustaining. Plasma CGRP levels are elevated during migraine attacks in both sexes, but the relationship between CGRP and female hormones adds a layer of complexity that makes women's migraine biology distinct.

Estrogen upregulates the gene expression for CGRP in trigeminal ganglia. When estrogen drops sharply at the end of the luteal phase, CGRP release increases acutely, which correlates with the onset of menstrual migraine. Progesterone appears to exert a partial modulatory effect on CGRP release, although the evidence here is limited and much of what is extrapolated about progesterone and CGRP comes from animal models rather than direct female clinical trials. That evidence gap is real and worth naming.

Pharmacokinetics in Women

Rimegepant reaches peak plasma concentration (Tmax) in approximately 90 minutes. Its half-life is roughly 11 hours. FDA prescribing information notes that women have approximately 20 to 30 percent higher rimegepant exposure (AUC) than men, a sex difference in pharmacokinetics attributed to differences in body weight and CYP3A4 metabolic activity. The approved dose is the same for both sexes, 75 mg, and no dose adjustment is currently recommended on the basis of sex alone. Clinicians should be aware that this higher exposure in women has not translated into a different dosing recommendation because the Phase 3 trials showed acceptable tolerability across the exposure range. The lack of sex-stratified efficacy and tolerability reporting in the primary trial publications remains a limitation.

What "Every Other Day" Means Physiologically

The every-other-day schedule is not arbitrary. Rimegepant's 11-hour half-life means that after 48 hours, the drug is substantially cleared. The every-other-day schedule keeps enough drug present during the high-risk period of each migraine cycle without reaching daily exposure levels that might increase the risk of medication-overuse headache (MOH). Traditional triptans and analgesics carry a well-established MOH risk with use more than 10 to 15 days per month. Gepants appear to carry a far lower MOH risk based on current data, though long-term post-marketing data are still accumulating.

The Missed-Dose Protocol: Exactly What to Do

The FDA label for Nurtec ODT does not include explicit missed-dose language for the preventive regimen, a gap that creates real confusion for patients and clinicians alike. The following protocol is synthesized from the drug's pharmacokinetic profile, the general principles of every-other-day dosing, and clinical practice standards.

If You Are Using Rimegepant for Acute Treatment (On-Demand)

There is no missed dose to manage. You take one 75 mg tablet when a migraine begins. If it has not worked adequately after two hours, you may not take a second tablet within 24 hours. There is no scheduled dosing to track, so there is nothing to miss.

If You Are Using Rimegepant for Prevention (Every Other Day)

Use this decision tree:

Step 1. Notice you have missed your scheduled every-other-day dose.

Step 2. Check how much time remains before your next scheduled dose. Your next dose would have been 48 hours after the missed one.

• If more than 12 hours remain before that next scheduled dose: take the missed dose now, then return to your regular every-other-day schedule from that point.
• If 12 hours or fewer remain: skip the missed dose entirely. Take your next dose at the originally scheduled time and continue the every-other-day pattern.

Step 3. Never take two 75 mg tablets within 24 hours regardless of the reason.

The 12-hour cutoff derives directly from the drug's half-life. At 12 hours before the next scheduled dose, taking a makeup dose would result in overlapping plasma concentrations that could push total daily exposure beyond the single-dose studied range.

Why Doubling Up Is a Problem

Rimegepant is metabolized by CYP3A4 and to a lesser degree by CYP2C9. Strong CYP3A4 inhibitors such as clarithromycin increase rimegepant AUC by approximately five-fold, and even a second dose within 24 hours adds exposure that has not been systematically studied for safety. The most common adverse effects in clinical trials, nausea (affecting approximately 2 percent in trials) and abdominal pain, are dose-related, and the theoretical risk of elevated hepatic transaminases, though not a prominent signal in Phase 3, warrants caution.

Practical Tip: The Calendar Method

Because the every-other-day schedule can drift after a missed dose or illness, keeping a simple paper or app-based calendar marking each dose day prevents the common problem of losing track of whether "today is a dose day." Several migraine diary apps, including Migraine Buddy and N1-Headache, allow custom medication reminders at 48-hour intervals.

Rimegepant for Menstrual and Hormonal Migraine

Women who experience perimenstrual migraine, meaning attacks that consistently begin one to two days before through two days after the onset of menstruation, represent a subgroup with particular need for an effective preventive strategy. Perimenstrual attacks are often longer, more severe, and less responsive to acute treatment than attacks at other cycle phases. Short-course prophylaxis with triptans (taken only around menstruation) has been studied, but rimegepant's every-other-day schedule provides continuous CGRP receptor blockade that does not require precise cycle tracking.

The Lancet 2021 randomized controlled trial of rimegepant 75 mg every other day enrolled adults with four to 14 monthly migraine days and showed a statistically significant reduction in mean monthly migraine days compared with placebo (difference of 1.7 days per month, 95% CI 0.9 to 2.5, p<0.0001) over 12 weeks. The trial was not powered to analyze a menstrual migraine subgroup specifically, and the published data do not separate outcomes by sex or hormonal status. That is a genuine gap that limits the precision of advice for women using rimegepant specifically for hormonal migraine.

Across Reproductive Life Stages

Reproductive years (no hormonal contraception). The every-other-day schedule runs continuously regardless of cycle phase. Some clinicians consider adding an acute dose on high-risk perimenstrual days, staying within the 24-hour limit, though this is not explicitly endorsed in the label.

Combined hormonal contraceptive users. Estrogen-containing contraceptives do not appear to alter rimegepant plasma levels in a clinically meaningful way based on the prescribing information, though sex-specific PK subgroup data from trials are sparse. Women who use combined hormonal contraceptives and have migraine with aura face a separate stroke-risk consideration that is independent of rimegepant.

Perimenopause. The hormonal chaos of perimenopause, characterized by erratic estrogen fluctuations and increasing migraine frequency in many women, makes the continuous CGRP blockade strategy of every-other-day rimegepant conceptually appealing. Formal clinical trial data in perimenopausal women using rimegepant are not yet available. Decisions should be individualized, particularly when menopausal hormone therapy is being considered concurrently.

Postmenopause. Migraine often improves after natural menopause for women whose attacks were hormonally driven, though this is not universal. If migraine persists postmenopausally, rimegepant is an option. No postmenopause-specific dose adjustment is described in the label.

Pregnancy, Lactation, and Contraception: What You Must Know

Rimegepant should be avoided during pregnancy. This is not a theoretical concern. Animal reproduction studies showed fetal harm at clinically relevant exposures. In rat studies, rimegepant caused increased embryo-fetal death and structural abnormalities at doses approximately 3.4 times the maximum recommended human dose. Human pregnancy data are essentially absent because pregnant women were excluded from clinical trials.

CGRP plays a physiologic role in maintaining uterine blood flow and modulating placental vascular tone. Blocking CGRP receptors during pregnancy has theoretical implications for placental perfusion that have not been adequately studied in humans. Given the combination of animal toxicity data and plausible biological mechanism, clinicians and patients should treat rimegepant as contraindicated in pregnancy until human safety data exist.

What to Use Instead During Pregnancy

Migraine during pregnancy is common, affecting approximately 15 to 20 percent of pregnant women at some point during gestation. Acetaminophen remains the preferred acute analgesic in pregnancy. For prevention, ACOG acknowledges that magnesium supplementation has the most favorable evidence profile among preventive options during pregnancy. Metoclopramide can be used for nausea associated with migraine in pregnancy. The decision to use any migraine treatment during pregnancy should involve a shared conversation between you and your obstetric provider.

Lactation

Rimegepant transfer into human breast milk has not been studied. FDA label language states that the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need and potential infant exposure. Rimegepant has a moderate molecular weight and moderate plasma protein binding, both of which suggest some level of milk transfer is possible, but quantitative data are absent. Women who are breastfeeding and need migraine prevention should discuss alternatives with their provider. Acetaminophen and low-dose aspirin (in consultation with a physician) have established lactation safety profiles for acute use.

Contraception Requirements

Rimegepant is not classified as a known teratogen in the same category as valproate or isotretinoin, but the animal data are concerning enough that women of reproductive potential should use effective contraception while taking it for prevention. Discuss your contraceptive plan with your prescribing clinician before starting the every-other-day preventive regimen. If you become pregnant while taking rimegepant, stop the medication and contact your provider promptly.

Who This Drug Is Right For and Who Should Pause

Women Who Are Good Candidates

• You have four or more monthly migraine days and have not adequately responded to or tolerated at least one oral preventive (propranolol, amitriptyline, topiramate, valproate).
• You have cardiovascular contraindications to triptans (uncontrolled hypertension, coronary artery disease, history of stroke) and need an acute option without vasoconstrictive effects.
• You experience perimenstrual migraine and want a continuous preventive without cycle-timed dosing.
• You are perimenopausal with increasing migraine frequency and are not currently pregnant or breastfeeding.
• You have had poor tolerability with anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) due to injection-site reactions or constipation, which are more common with monoclonal antibodies than with oral gepants.

Women Who Should Use Rimegepant With Caution or Not at All

• Pregnancy: avoid. The embryo-fetal risk based on animal data is real.
• Breastfeeding: insufficient data; individualize with your provider.
• Severe hepatic impairment: rimegepant is hepatically metabolized and the label recommends avoiding use in severe hepatic impairment.
• Strong CYP3A4 inhibitors: drugs such as clarithromycin, ketoconazole, and itraconazole dramatically increase rimegepant plasma levels; avoid concurrent use or dose-adjust other medications under physician guidance.
• Women taking rifampin or other strong CYP3A4 inducers: these reduce rimegepant exposure substantially, potentially rendering it ineffective.

Drug Interactions Specific to Women's Common Prescriptions

Women are disproportionately prescribed certain drug classes that interact with rimegepant's metabolic pathway.

Oral contraceptives. Combined oral contraceptives contain ethinyl estradiol, which is primarily CYP3A4-metabolized. The prescribing information does not flag a specific interaction between rimegepant and oral contraceptives, but women on COCs and rimegepant should be aware that adding or removing CYP3A4-active drugs to their regimen can shift exposures in both directions.

Antidepressants. SSRIs and SNRIs are among the most commonly prescribed drugs in women of reproductive age, and some SNRIs are mild CYP2D6 or CYP3A4 modulators. Fluoxetine is a moderate CYP3A4 inhibitor. Women on fluoxetine and rimegepant may have modestly higher rimegepant exposure. The clinical significance of this interaction has not been studied specifically, but it is something your pharmacist or prescribing clinician should review.

Antiepileptics for migraine prevention. Topiramate and valproate are used for migraine prevention. Both have significant pharmacokinetic interaction profiles. Valproate inhibits several CYP enzymes; topiramate at higher doses weakly inhibits CYP2C19. If you are transitioning from one of these to rimegepant, discuss the washout and overlap plan with your neurologist.

Thyroid medications. Levothyroxine does not interact with rimegepant via CYP pathways, and no interaction is documented. Women on stable thyroid hormone replacement do not need dosing adjustments for either drug.

Monitoring: How to Know If Rimegepant Is Working

Clinical trials use a 50 percent responder rate as the standard efficacy threshold, meaning at least a 50 percent reduction in monthly migraine days from baseline. The Lancet 2021 trial reported that approximately 49 percent of rimegepant-treated patients achieved a 50 percent or greater reduction in monthly migraine days over 12 weeks, compared with approximately 41 percent in the placebo group. That difference, while statistically significant, is modest in absolute terms. An honest conversation about expectations matters before starting.

A reasonable clinical review point is at 12 weeks. Keep a headache diary from the first day you start rimegepant for prevention. Track:

• Number of migraine days per month
• Number of acute doses needed per month (whether rimegepant or another rescue medication)
• Any adverse effects (nausea, abdominal discomfort, hypersensitivity reactions)
• Cycle phase at attack onset if you are menstruating

"The question I ask every patient at the 12-week mark is not just 'are you having fewer migraines' but 'are you using fewer acute medications?' Because if the preventive is working, rescue use should drop even if total migraine days don't change dramatically," says Rachel Goldberg, MD, WomanRx medical reviewer. "For women with hormonal migraine, I also ask whether the perimenstrual attacks are shorter or more responsive to acute treatment. That's a signal the preventive is doing something even before the migraine-day count moves."

Nurtec ODT Storage and Handling: The Practicalities

Each tablet is packaged individually in a foil blister pack. Store at room temperature, 68 to 77 degrees Fahrenheit. Do not store in a bathroom medicine cabinet where humidity fluctuates. The ODT format is moisture-sensitive. Carry individual blister packs in a small zip-lock bag in your purse or travel kit rather than loose in a pill organizer, where humidity could pre-dissolve the tablet.

Shelf life after dispensing follows the manufacturer expiration date printed on the carton. Do not use a tablet that has cracked, become soft, or looks discolored before you place it on your tongue.

Restarting Rimegepant After a Break

If you have stopped rimegepant for any reason (pregnancy, surgery, medication trial pause, insurance interruption) and are restarting, no loading dose or titration is required. Resume the standard 75 mg every-other-day schedule on day one of restart. You will not regain preventive efficacy immediately. The Lancet 2021 trial showed that efficacy accumulated over the 12-week treatment period, so give the drug at least eight to 12 weeks before evaluating whether it is working for prevention. For acute use, the drug works within two hours of a single dose and does not require any lead-in period.